Volume 103, Issue 1 pp. 153-159
ORIGINAL ARTICLE - CLINICAL SCIENCE

Transcatheter mitral valve replacement with Mi-thos system: First-in-human experience

Ye Yang MD

Ye Yang MD

Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

Search for more papers by this author
Jinmiao Chen MD, PhD

Jinmiao Chen MD, PhD

Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

Search for more papers by this author
Lili Dong MD, PhD

Lili Dong MD, PhD

Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai, China

Search for more papers by this author
Yuntao Lu MD

Yuntao Lu MD

Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

Search for more papers by this author
Minzhi Lv MD

Minzhi Lv MD

Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, China

Search for more papers by this author
Kefang Guo MD

Kefang Guo MD

Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China

Search for more papers by this author
Ghufran Bagaber MBBS

Ghufran Bagaber MBBS

Shanghai Medical College, Fudan University, Shanghai, China

Search for more papers by this author
Jian Yang MD, PhD

Jian Yang MD, PhD

Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, Xi'an, China

Search for more papers by this author
Chunsheng Wang MD

Chunsheng Wang MD

Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

Search for more papers by this author
Lai Wei MD, PhD

Corresponding Author

Lai Wei MD, PhD

Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

Correspondence Lai Wei, MD, PhD, Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Rd, Shanghai 200032, China.

Email: [email protected]

Search for more papers by this author
First published: 09 December 2023
Citations: 2

Ye Yang, Jinmiao Chen and Lili Dong contributed equally as the co-first authors.

Abstract

Background

Transcatheter mitral valve replacement (TMVR) has become an alternative for high-risk patients with severe mitral regurgitation (MR). The aim of this study was to evaluate the safety and feasibility of the Mi-thos TMVR system (NewMed Medical) for high-risk patients with severe MR.

Methods

This was a prospective, two-center, single-arm early feasibility study. Baseline characteristics, procedural data and 30-day follow-up outcomes were collected and analyzed. The primary endpoint was intraoperative success rate of device implantation. The second endpoints were all-cause mortality and major post-procedural complications. Echocardiographic data were evaluated by an independent core laboratory. Clinical events were adjudicated by a clinical events committee.

Results

Ten high-risk patients with severe MR were enrolled at two sites from August 2021 to November 2022. The median age was 70.5 years, and 60% of patients were female. The median Society of Thoracic Surgeons Predicted Risk of Mortality was 9.5%. The Mi-thos TMVR system was successfully implanted via transapical access in all patients. There was no pericedural mortality or major postpericedural complications during the 30-day follow-up. All implanted prosthetic valves had no or trace valvular or paravalvular MR, and the median mitral valve gradient at 30 days was 2.0 mmHg (IQR: 2.0–3.0 mmHg). There was one mild left ventricular outflow tract obstruction.

Conclusions

The favorable short-term outcomes of the Mi-thos TMVR system demonstrated that it might be a feasible and safe therapeutic alternative for high-risk patients with severe MR. Nevertheless, further evaluation of the Mi-thos TMVR system is warranted.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available by request.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.